Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Active not recruiting 2 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12 Gastrointestinal 8 Thoracic 3 Other hematologic neoplasm 3 Head & Neck 3 Tumor-Agnostic 2 Lymphoid 2 Sarcoma 1 Gynecologic 1 Genitourinary 1 CNS 1

Conditions

Prostatic Neoplasms 1 Lung Neoplasms 1

Interventions

Docetaxel 33 Radiosurgery 22 Radiotherapy 21 Sunitinib 20 pembrolizumab 17 Gemcitabine 16 Cisplatin 16 Androgen Antagonists 15 enzalutamide 13 Nivolumab 13 Goserelin 12 Blood Specimen Collection 12 aldesleukin 11 Surveys and Questionnaires 11 Prednisone 11 Leuprolide 11 Cyclophosphamide 11 Abiraterone Acetate 11 Bevacizumab 10 bicalutamide 9 Multiparametric Magnetic Resonance Imaging 9 Carboplatin 9 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8 Gonadotropin-Releasing Hormone 8 Filgrastim 8 Epirubicin 8 Chemotherapy, Adjuvant 8 Brachytherapy 8 toripalimab 7 tislelizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Control Groups × Genitourinary × Clear all

NCT05319145 2022-04-13

PROFIT

Hospital Universitari Vall d'Hebron Research Institute

Phase NA Unknown

GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡